. Author manuscript; available in PMC: 2020 May 22.

Published in final edited form as: Clin J Oncol Nurs. 2010 Aug;14(4):419–422. doi: 10.1188/10.CJON.419-422

Table 2.

Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: Predictors of Progression

RISK FACTOR	MAYO CLINIC (%)^a	PETHEMA (%)^b
0	5	2
1	21	10
2	37	46
3	58	-

Progression was assessed at 20 years. Risk factors were monoclonal protein higher than 1.5 g/dl, immunoglobulin A or M monoclonal gammopathy of undetermined significance, and serum-free light chain ratio lower than 0.26 or higher than 1.65.

Progression was assessed at five years. Risk factors were 95% or higher abnormal plasma cells by flow cytometry and DNA aneuploidy by flow cytometry.

PETHEMA—Programa Para el Estudio de la Terapéutica en Hemopatía Maligna (Program for the Study of Therapy in Hematologic Malignancies)

Note. Based on information from Perez-Persona et al., 2007; Rajkumar et al., 2005.